Research
Hormonal
Obesity in females is correlated with menstrual abnormalities, infertility, and complications during gestation.
Clinicians should assess reproductive health in obese female patients.
StrongSupportsmedium confidence
In the female population, obesity has been correlated with menstrual abnormalities, infertility, and complications during gestation.
Why this rating
The review compiles evidence on the reproductive impacts of obesity.
Source
Reproduction and Anti-Obesity Medications: A Review of Current Evidence
Héctor Iván Saldívar-Cerón · The Journal of Reproduction · 2023
DOI 10.58779/issn.2954-467x.tjor2023.v2.n2.27
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →